Candida urinary tract infections--treatment

Area of Science:

• Mycology
• Infectious Diseases
• Clinical Pharmacology

Background:

• Candiduria, the presence of Candida in urine, frequently represents asymptomatic colonization or contamination rather than invasive fungal infection.
• Distinguishing true Candida urinary tract infections (UTIs) from colonization is crucial for appropriate patient management.
• Antifungal therapy for candiduria is not universally indicated and depends on clinical context and patient factors.

Purpose of the Study:

• To review the diagnostic considerations and therapeutic strategies for managing Candida urinary tract infections.
• To evaluate the role of various antifungal agents in treating UTIs caused by Candida species.
• To highlight factors influencing the choice of antifungal therapy and adjunctive treatments.

Main Methods:

• Literature review of studies on candiduria and Candida UTIs.
• Analysis of clinical guidelines and expert opinions on antifungal drug selection.
• Evaluation of pharmacokinetic and pharmacodynamic properties of antifungal agents relevant to UTIs.

Main Results:

• Fluconazole is the preferred agent for Candida UTIs due to its safety profile, high urinary concentrations, and availability in oral and IV forms.
• Flucytosine and low-dose amphotericin B are options in selected cases, requiring careful monitoring for toxicity.
• The efficacy of echinocandins and certain azoles with low urinary concentrations remains uncertain, with mixed results reported.

Conclusions:

• Accurate diagnosis of invasive candiduria versus colonization is paramount.
• Treatment of symptomatic Candida UTIs should be guided by patient status, infection site, and drug properties, with fluconazole often being the first choice.
• While systemic therapy is primary, adjunctive measures like bladder irrigation or renal pelvis irrigation may be useful in specific situations, such as fungus balls.